Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Richard RauckAndrew L Finn

Abstract

Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer. The objective of this study was to evaluate the efficacy of FBSF at doses of 200-1200 microg in the management of breakthrough pain in patients with cancer receiving ongoing opioid therapy. This was a multicenter, randomized, double-blind, placebo-controlled, multiple-crossover study that included opioid-tolerant adult patients with chronic cancer pain who experienced one to four daily episodes of breakthrough pain. The primary efficacy assessment was the sum of pain intensity differences at 30 min (SPID30) postdose. The intent-to-treat population consisted of 80 patients with > or =1 post-baseline efficacy assessment. The least-squares mean (LSM +/- SEM) of the SPID30 was significantly greater for FBSF-treated episodes of breakthrough pain than for placebo-treated episodes (47.9 +/- 3.9 versus 38.1 +/- 4.3; P = 0.004). There was statistical separation from placebo starting at 15 min up through 60 min (last time point assessed). There were no unexpected adverse events (AEs) or clinically significant safety findings. FBSF is an effective option for control of breakthrough pain in patients receiving ...Continue Reading

References

Jun 1, 1990·Pain·R K Portenoy, N A Hagen
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F De ConnoC Ripamonti
Jul 20, 2002·Clinical Pharmacokinetics·Hao ZhangJames B Streisand
Dec 24, 1955·Journal of the American Medical Association·H K BEECHER
Dec 26, 1955·Minerva medica·L SCHIAVETTI, F FERRARIS
Jun 17, 2004·Palliative Medicine·Augusto CaraceniUNKNOWN Working Group of an IASP Task Force on Cancer Pain
Aug 2, 2007·Annual Review of Pharmacology and Toxicology·Fabrizio Benedetti
May 7, 2008·Drugs·Leeroy William, Rod Macleod
Aug 1, 2008·Neuron·Paul EnckManfred Schedlowski
Feb 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H BreivikL Dow

❮ Previous
Next ❯

Citations

Oct 27, 2012·Clinical Pharmacokinetics·Jörn LötschGerd Geisslinger
Mar 15, 2014·Current Medical Research and Opinion·Sebastiano Mercadante, Antonino Giarratano
Aug 29, 2013·Journal of Pain and Symptom Management·Giovambattista ZeppetellaJeroen P Jansen
May 26, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Viralkumar F PatelMarc B Brown
Jan 14, 2011·Clinical Oncology : a Journal of the Royal College of Radiologists·G Zeppetella
Jan 10, 2012·Pain Practice : the Official Journal of World Institute of Pain·Srinivas R NalamachuJulian Howell
May 6, 2011·CA: a Cancer Journal for Clinicians·Judith A Paice, Betty Ferrell
Aug 13, 2011·Pain Practice : the Official Journal of World Institute of Pain·Mona Darwish, Fang Xie
Mar 24, 2016·Clinical Drug Investigation·Karly P Garnock-Jones
Sep 15, 2015·Journal of Pain & Palliative Care Pharmacotherapy·Andrew ChangJoseph D Ma
Oct 13, 2015·Journal of Pain & Palliative Care Pharmacotherapy·Dulce RogríguezMaite Murillo
Jul 26, 2014·Pain Practice : the Official Journal of World Institute of Pain·Richard RauckLisa Stearns
Apr 25, 2014·Current Pain and Headache Reports·Andrew N Davies
May 17, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Pedro M CastroManuela E Pintado
Jul 10, 2012·Journal of Pain and Symptom Management·Robert TwycrossAndrew Wilcock
Aug 28, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sebastiano Mercadante, Arturo Cuomo
Oct 18, 2014·Acupuncture in Medicine : Journal of the British Medical Acupuncture Society·Carole A Paley, Mark I Johnson
Jul 31, 2010·Palliative Medicine·Neil A HagenCarla R Stiles
Aug 16, 2011·British Journal of Nursing : BJN·Andrew N Davies
May 8, 2018·European Journal of Hospital Pharmacy. Science and Practice·Robert JanknegtMorten Thronaes
Jan 21, 2019·Clinical Pharmacology and Therapeutics·Jennifer S GewandterRobert H Dworkin
Sep 23, 2016·Pain·Sebastiano Mercadante, Russell K Portenoy
May 20, 2017·Clinical Journal of Oncology Nursing·Jeannine M BrantThiruppavai Sundaramurthi
Jun 8, 2018·BMJ Supportive & Palliative Care·Andrew Neil DaviesKath Webber
Dec 14, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Sebastiano MercadanteAlessandra Casuccio
Aug 30, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Eva Katharina MaselHerbert Hans Watzke
Sep 3, 2010·Pain Practice : the Official Journal of World Institute of Pain·Ulrich R KleebergGiovambattista Zeppetella
Aug 15, 2015·The Cochrane Database of Systematic Reviews·Giovambattista Zeppetella, Andrew N Davies
Feb 27, 2018·Expert Review of Anticancer Therapy·Sebastiano Mercadante
Jan 12, 2012·Drugs·Sebastiano Mercadante
Dec 30, 2017·Expert Opinion on Drug Delivery·Yasmin ThabetJörg Breitkreutz
Feb 1, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C Camps HerreroV Guillem Porta

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.